<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113163</url>
  </required_header>
  <id_info>
    <org_study_id>TP-101-CS01</org_study_id>
    <nct_id>NCT02113163</nct_id>
  </id_info>
  <brief_title>PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA</brief_title>
  <official_title>An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thetis Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thetis Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to contrast the pharmacokinetic profiles of metformin
      and EPA delivered separately as co-administered products (metformin hydrochloride or
      Glucophage and icosapent ethyl or Vascepa) and together as the solid dose form (metformin
      eicosapentaenoate or TP-101) under fasted and fed conditions. A secondary objective is to
      evaluate the safety and tolerability of single and repeat single doses of TP-101.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and Vascepa</measure>
    <time_frame>PK samples at 0, 0.5, 1, 2, 4, 8, and 12 hours following drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Cohort A - Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin Eicosapentaenoate 1500 mg or Metformin HCl 500 mg and Vascepa 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B - High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin Eicosapentaenoate 3000 mg or Metformin HCl 1000 mg and Vascepa 2000 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Eicosapentaenoate</intervention_name>
    <arm_group_label>Cohort A - Low Dose</arm_group_label>
    <arm_group_label>Cohort B - High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin HCl and Vascepa</intervention_name>
    <arm_group_label>Cohort A - Low Dose</arm_group_label>
    <arm_group_label>Cohort B - High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent executed prior to protocol screening assessments;

          -  Men or women 18 to 65 years of age, inclusive (Women may be surgically sterile via
             tubal ligation, bilateral oophorectomy or hysterectomy or who are postmenopausal for
             &gt;1 year. Women who are of childbearing potential must agree to practice adequate
             contraception one month before the first dose of study medication and up to Day 16 of
             the study. Adequate contraception may include, but is not limited to, abstinence,
             monogamous relationship with vasectomized partner, barrier methods such as condoms or
             diaphragms with spermicide or foam, intrauterine devices, and licensed hormonal
             methods.);

          -  No history of chronic diseases, except for subjects with well-controlled hypertension
             or well-controlled hyperlipidemia;

          -  BMI â‰¤30kg/m2;

          -  No significant medical history including diabetes or hypertension complicated by
             hyperlipidemia (metabolic syndrome);

          -  Negative urine drug and alcohol tests at Screening; and,

          -  No metformin or omega-3 products within 2 months.

        Exclusion Criteria:

          -  Abnormal findings on physical examination, EKG, vital signs, and clinical laboratory
             testing, in the judgment of the investigator;

          -  Allergies to fish or shellfish;

          -  Impaired renal function (calculated eGFR &lt;60 mL/min);

          -  Abnormal laboratory values for T3, T4 and TSH at the Screening Visit;

          -  Aspartate aminotransferase/alanine aminotransferase (AST/ALT) &gt;2x upper limits of
             normal (ULN) or serum bilirubin &gt;1.5 mg/dL;

          -  Requirement of prescription medication within 14 days of the Screening Visit, with the
             exception of prescription medications for the prevention of pregnancy, anti
             hypertensives for hypertension, or statins for hyperlipidemia. Doses of one or two
             anti-hypertensives and/or a statin must be stable for &gt;1 month;

          -  Normal doses of over-the-counter medications, including vitamins are allowed but not
             within 3 days of Visit 2 (first day of dosing);

          -  Current or history of abuse of alcohol or illicit drugs within the preceding year to
             the Screening Visit;

          -  Participation in a dietary modification or an intensive weight loss program;

          -  Participation in another clinical trial of an investigational product within 3 months
             prior to the Screening Visit;

          -  Smokers (use of tobacco in the past 3 months); or,

          -  Donation or loss of 400 mL blood or more in the last 8 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lauren Harrington, RN</last_name>
    <phone>225-763-2699</phone>
    <email>Lauren.Harrington@pbrc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tance Sonnier</last_name>
    <phone>225-763-2623</phone>
    <email>Tance.Sonnier@pbrc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frank Greenway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>April 10, 2014</last_update_submitted>
  <last_update_submitted_qc>April 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>T2DM</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>severe hypertriglyceridemia</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>triglycerides</keyword>
  <keyword>lipids</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>EPA</keyword>
  <keyword>ethyl-EPA</keyword>
  <keyword>Metformin</keyword>
  <keyword>Glucophage</keyword>
  <keyword>Lovaza</keyword>
  <keyword>Vascepa</keyword>
  <keyword>Epanova</keyword>
  <keyword>Astra Zeneca</keyword>
  <keyword>Amarin</keyword>
  <keyword>GSK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

